Therapy
Health
Cancer Prevention

Inovio

$2.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.18 (8.22%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Inovio and other stocks, options, ETFs, and crypto commission-free!

About INO

Inovio Pharmaceuticals, Inc. Common Stock, also called Inovio, is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Read More Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Employees
281
Headquarters
Plymouth Meeting, Pennsylvania
Founded
1983
Market Cap
234.70M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
653.31K
High Today
$2.40
Low Today
$2.21
Open Price
$2.22
Volume
506.29K
52 Week High
$6.30
52 Week Low
$2.15

Collections

Therapy
Health
Cancer Prevention
Medical
Pharmaceutical
Technology

INO News

ReutersAug 9

Edited Transcript of INO earnings conference call or presentation 8-Aug-19 8:30pm GMT

93

INO Earnings

-$0.36
-$0.27
-$0.17
-$0.08
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.27 per share
Actual
-$0.30 per share

Popular Stocks

More INO News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.